Catalyst
Slingshot members are tracking this event:
PDUFA date for Vertex Pharmaceutical's Tezacaftor, in combination with ivacaftor as a treatment for cystic fibrosis in paitents 12 years of age and older who have certain genetic markers, is set for February 28, 2018
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| VRTX |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 12, 2018
Occurred Source:
http://investors.vrtx.com/releasedetail.cfm?ReleaseID=1057241
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Cystic Fibrosis, Tezacaftor, Cftr, F508del-cftr Mutation
